XML 56 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock Based Compensation (Tables)
12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of Weighted-average for Each of The Assumptions The Company Used to Determine The Grant-date Fair Value of Options Granted

The weighted-average for each of the assumptions the Company used to determine the grant-date fair value of options granted were as follows:

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

Risk free interest rate

 

 

3.95

%

 

 

2.40

%

Expected term (in years)

 

 

6.36

 

 

 

6.24

 

Expected dividend yield

 

 

0

%

 

 

0

%

Expected volatility of underlying common stock

 

 

87

%

 

 

81

%

 

Summary of Stock Option Activity

The following table summarizes the stock option activity:

 

 

 

Stock
Options

 

 

Weighted
Average
Exercise
Price

 

 

Weighted
Average
Remaining
Life
(in Years)

 

 

Intrinsic
Value
(in
thousands)

 

Outstanding January 1, 2023

 

 

5,230,537

 

 

$

5.35

 

 

 

8.49

 

 

$

 

Granted

 

 

8,544,660

 

 

 

2.70

 

 

 

 

 

 

 

Exercised

 

 

(316,441

)

 

 

2.25

 

 

 

 

 

 

 

Canceled

 

 

(3,060,506

)

 

 

5.10

 

 

 

 

 

 

 

Outstanding December 31, 2023

 

 

10,398,250

 

 

$

3.34

 

 

 

8.87

 

 

$

28,278

 

Options vested or expected to vest as of December 31, 2023

 

 

10,398,250

 

 

$

3.34

 

 

 

8.87

 

 

$

28,278

 

Stock options exercisable as of December 31, 2023

 

 

1,765,282

 

 

$

4.88

 

 

 

6.97

 

 

$

3,016

 

Summary of Other Information Related to Option Activity

Other information related to the option activity for the years ended December 31, 2023 and 2022:

 

 

Year Ended
December 31,

 

 

 

2023

 

 

2022

 

Weighted-average fair value of options granted

 

$

2.17

 

 

$

2.80

 

Intrinsic value of options exercised (in thousands)

 

 

152

 

 

 

62

 

Summary of Stock-based Compensation Expense

Stock-based compensation expense related to stock options and the stock purchase plan for the years ended December 31, 2023 and 2022 was classified in the consolidated statement of operations as follows (in thousands):

 

 

 

Year Ended
December 31,

 

 

 

2023

 

 

2022

 

Research and development

 

$

2,876

 

 

$

1,626

 

General and administrative

 

 

2,332

 

 

 

2,925

 

Total stock-based compensation expense

 

$

5,208

 

 

$

4,551

 

S